New shot could tame stubborn hives when pills fail
NCT ID NCT07402213
First seen Jun 27, 2026 · Last updated Aug 04, 2026 · Updated 2 times
Summary
This study tests an injection called JYB1904 in 180 adults with chronic spontaneous urticaria (hives and itching lasting over 6 weeks) that isn't well controlled by standard antihistamines. Participants receive either the drug or a placebo every 12 weeks for 48 weeks. The main goal is to see if the drug reduces hive activity and itching scores after 12 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- JYB1904 injection
- What this could lead to
- If it works, this could provide a new treatment option for people with chronic hives that don't respond well to standard antihistamines.
- What could go wrong
- This is an early Phase 3 trial with only 180 participants, so results may not apply to everyone. The drug may not prove more effective than placebo, and side effects are still being studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC SPONTANEOUS URTICARIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University People's Hospital
RECRUITINGBeijing, 100044, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a diet tame chronic hives in teens?
- Can a new pill silence the itch of chronic hives?
- New drug aims to quiet chronic hives
- New pill for chronic hives enters first human tests
- New pill for chronic hives tested in everyday clinics
- New hope for chronic hive sufferers: phase 3 drug trial shows promise